



(51) International Patent Classification:

C07D 403/12 (2006.01) *C07D 317/20* (2006.01)
C07D 205/04 (2006.01) *C07D 317/24* (2006.01)
A61K 31/506 (2006.01) *C07C 69/92* (2006.01)

(21) International Application Number:

PCT/GB2012/051620

(22) International Filing Date:

10 July 2012 (10.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/506,737 12 July 2011 (12.07.2011) US

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London, Greater London W2 6BD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CONNOLLY, Stephen** [GB/SE]; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **EBDEN, Mark, Richard** [GB/GB]; C/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **LANGER, Thomas** [DE/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **STEVEN, Alan, Robert** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **STEWART, Craig, Robert** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **TOMLIN, Paula, Margaret** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **WALTERS, Iain, Alastair, Stewart** [GB/GB]; C/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **WILLIAMS, Andrew, John** [GB/GB]; AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(74) Agents: **ASTRAZENECA INTELLECTUAL PROPERTY** et al.; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: N- (6- ((2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3-METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR



(57) Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with international search report (Art. 21(3))*
GW, ML, MR, NE, SN, TD, TG).